The Team
Meet the DABRA Veterans Leading IEVC
Dean Irwin - Founder and C.E.O.
Mr. Irwin brings over four decades of management and product development experience to the founding team. Prior to his six years as CEO of CyMeda, Inc, Mr. Irwin was co-founder, Chairman, CEO, and CTO of Ra Medical Systems, Inc. (NYSE:RMED) from 2002 to 2019 where he invented the Pharos dermatological system and the DABRA Vascular system. He took the company to IPO in the NYSE big board in 2018. Prior to that he was the Vice President of Research & Development and V.P. of Engineering for PhotoMedex (NASDAQ:PHMD), where he invented laser systems for cardiovascular surgery and dermatology, including the XTRAC. Prior to his tenure at PhotoMedex, Mr. Irwin was Vice President of Engineering and General Manager at Spatialight, Inc. (NASDAQ:HDTV) where he developed award-winning electro-optical components and systems. Mr. Irwin was also a founder and chief scientist of DIR Corporation and has held various engineering positions with Acculase, General Atomics, and Universal Voltronics Corporation. In addition, he has consulted for the Plasma Research Center at the Massachusetts Institute of Technology (MIT), the Institute of Plasma Physics at Nagoya University in Japan, Borland International, and Intel Corporation. Mr. Irwin has been issued twenty-nine patents in the field of electro-optics and has published numerous engineering and scientific papers. He has also authored and received FDA 510(k) clearances, KFDA (Korea), CFDA (China), and CE (EU) mark. He has run several successful clinical trials to support FDA acceptance, both PMA and 510(k)s.
Melissa Burstein- Director
Prior to IEVC and CyMeda, Ms. Burstein co-founded Ra Medical Systems and served as its Executive Vice President, Secretary, and a Director from September 2002 to 2019. During her tenure, Ms. Burstein scaled the organization from startup through its IPO (NYSE: RMED), supporting the Pharos and DABRA launches and growth to a 140-person team. Prior to Ra Medical, Ms. Burstein led product launches and marketing initiatives at Eli Lilly (Lilly) and Amylin Pharmaceuticals (acquired by Bristol-Myers Squibb), developing patient and professional communications within regulated healthcare environments. She specializes in translating complex clinical and technical concepts into clear, compelling messaging that resonates with target audiences and delivers results across U.S. and international markets. Ms. Burstein holds an MBA specializing in international management from Thunderbird, the American Graduate School of International Management, and a B.S. from Georgetown University.
Richard Heymann - Director
Prior to IEVC, Mr. Heymann served as a Director of Ra Medical Systems from July 2008 to 2018 and as an employee in Corporate Strategy and Business Development from January 2016 to 2018. Mr. Heymann has served as the President and Chief Executive Officer of Noteworthy Advisors, a finance and real estate consulting firm specializing in acquisitions and brokerage since July 2002. Prior to his role at Noteworthy Advisors, Mr. Heymann served as President of Security Financial Bancorp, a real estate, private lender and investment company from 1992 to July 2002. Mr. Heymann attended the University of Wisconsin and holds a B.A. from Idaho State University. Mr. Heymann brings business acumen and deep understanding of our company, values, and DABRA to IEVC's Board.
